Singer Blanton (suededomain09)

Weight management seems to be beneficial for obese atrial fibrillation (AF) patients; however, randomised data are sparse. Thus, this study aimed to investigate the influence of weight reduction on AF-ablation outcomes. SORT-AF is an investigator-sponsored, prospective, randomised, multicenter, clinical trial. Patients with symptomatic AF (paroxysmal or persistent) and Body-Mass-Index (BMI) 30-40kg/m2 underwent AF-ablation and were randomised to either weight-reduction (group-1) or usual care (group-2), after sleep-apnea-screening and loop recorder (ILR) implantation. The primary endpoint was defined as AF-burden between 3-12 months after AF-ablation. Overall, 133 patients (60±10 years, 57% persistent AF) were randomised to group-1 (n = 67) and group-2 (n = 66), respectively. Complications after AF-ablation were rare (one stroke, no tamponade). The intervention led to a significant reduction of BMI (34.9±2.6 to 33.4±3.6) in group-1 compared to a stable BMI in group-2 (p < 0.001). AF-burden after ablament of exercise activity were beneficial for obese patients with persistent AF demonstrating the relevance of life-style management as an important adjunct to AF-ablation in this setting. A genetic predisposition to lower thyrotropin (TSH) levels is associated with increased atrial fibrillation (AF) risk through undefined mechanisms. Defining the genetic mediating mechanisms could lead to improved targeted therapies to mitigate AF risk. We used 2-sample mendelian randomization (MR) to test associations between TSH-associated single-nucleotide variations and 16 candidate mediators. We then performed multivariable mendelian randomization (MVMR) to test for a significant attenuation of the genetic association between TSH and AF, after adjusting for each mediator significantly associated with TSH. Four candidate mediators (free thyroxine, systolic blood pressure, heart rate, and height) were significantly inversely associated with genetically predicted TSH after adjusting for multiple testing. In MVMR analyses, adjusting for height significantly decreased the magnitude of the association between TSH and AF from -0.12 (SE 0.02) occurrences of AF per SD change in height to -0.06 (0.02) (P = .005). Adjusting for the other candidate mediators did not significantly attenuate the association. The genetic association between TSH and increased AF risk is mediated, in part, by taller stature. Thus, some genetic mechanisms underlying TSH variability may contribute to AF risk through mechanisms determining height occurring early in life that differ from those driven by thyroid hormone-level elevations in later life. The genetic association between TSH and increased AF risk is mediated, in part, by taller stature. Thus, some genetic mechanisms underlying TSH variability may contribute to AF risk through mechanisms determining height occurring early in life that differ from those driven by thyroid hormone-level elevations in later life. We quantify the use of clinical decision support (CDS) and the specific barriers reported by ambulatory clinics and examine whether CDS utilization and barriers differed based on clinics' affiliation with health systems, providing a benchmark for future empirical research and policies related to this topic. Despite much discussion at the theoretic level, the existing literature provides little empirical understanding of barriers to using CDS in ambulatory care. We analyze data from 821 clinics in 117 medical groups, based on in Minnesota Community Measurement's annual Health Information Technology Survey (2014-2016). We examine clinics' use of 7 CDS tools, along with 7 barriers in 3 areas (resource, user acceptance, and technology). Employing linear probability models, we examine factors associated with CDS barriers. Clinics in health systems used more CDS tools than did clinics not in systems (24 p